Expression of toll-like receptors in recurrent pleomorphic adenoma and carcinoma ex pleomorphic adenoma

被引:0
作者
Jauhiainen, Maria K. [1 ,2 ,3 ,4 ]
Markkanen, Anttoni [5 ]
Atula, Timo [1 ,2 ]
Aro, Katri [1 ,2 ]
Haglund, Caj [2 ,5 ,6 ,7 ]
Soederlund-Venermo, Maria [3 ]
Maekitie, Antti A. [1 ,2 ,4 ]
Sinkkonen, Saku T. [1 ,2 ]
Hagstroem, Jaana [5 ,6 ,8 ]
机构
[1] Helsinki Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland
[2] Univ Helsinki, Helsinki, Finland
[3] Univ Helsinki, Dept Virol, Helsinki, Finland
[4] Univ Helsinki, Res Program Syst Oncol, Fac Med, Helsinki, Finland
[5] Univ Hosp Helsinki & Turku, Dept Pathol, Helsinki, Finland
[6] Univ Helsinki, Res Programs Unit, Translat Canc Med, Fac Med, Helsinki, Finland
[7] Helsinki Univ Hosp, Dept Surg, Helsinki, Finland
[8] Univ Turku, Dept Oral Pathol & Radiol, Turku, Finland
关键词
Salivary gland; virus; immunity; parotid gland; immunohistochemistry; ACTIVATION;
D O I
10.1111/apm.13505
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pleomorphic adenoma (PA) is a benign salivary gland tumour that may recur or undergo malignant transformation (CXPA). Toll-like receptors (TLR) mediate immune responses triggered by various agents such as viruses and are related to tumour formation either by stimulating or suppressing their growth, with variation across different tumour entities. We compared TLR immunohistochemical expression in PA, its recurrent counterparts and CXPA and evaluated the effect of virus presence in these tumours. We studied the expression of TLR-2, -3, -5, -7 and -9 in 25 PA, 34 recurrent PA and 15 CXPA tumour samples. In addition, we examined the TLR expression levels in the presence and absence of herpes-, polyoma- and parvovirus DNA in a subset of tumours (n=20). CXPA expressed significantly more TLR-5 and TLR-9 in the nucleus, cytoplasm and cell membrane compared with benign PA. The presence of virus DNA did not notably affect the TLR expression. TLR expression patterns seem to reflect tumour behaviour but are independent of the presence of viruses tested in this study.
引用
收藏
页数:8
相关论文
共 27 条
  • [1] Repeatedly recurring pleomorphic adenoma: a therapeutic challenge
    Aro, K.
    Valle, J.
    Tarkkanen, J.
    Makitie, A.
    Atula, T.
    [J]. ACTA OTORHINOLARYNGOLOGICA ITALICA, 2019, 39 (03) : 156 - 161
  • [2] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545
  • [3] Meta-analysis of surgical approaches to the treatment of parotid pleomorphic adenomas and recurrence rates
    Colella, Giuseppe
    Cannavale, Rosangela
    Chiodini, Paolo
    [J]. JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2015, 43 (06) : 738 - 745
  • [4] Dajon M., 2017, TollLike Receptor Stimulation in Cancer: A Pro and AntiTumor DoubleEdged Sword, V222, P89
  • [5] Clinical and Oncological Impact of the Toll-like Receptor-3 and-4 in Esophageal and Gastro-esophageal Junction Adenocarcinoma
    Davakis, Spyridon
    Kapelouzou, Alkistis
    Sakellariou, Stratigoula
    Kyriakoulis, Konstantinos G.
    Mylonakis, Adam
    Papadakos, Stavros P.
    Mpoura, Maria
    Vailas, Michail
    Ziogas, Dimitrios
    Liakakos, Theodoros
    Charalabopoulos, Alexandros
    [J]. ANTICANCER RESEARCH, 2023, 43 (07) : 3183 - 3191
  • [6] Toll-like Receptors and the Control of Immunity
    Fitzgerald, Katherine A.
    Kagan, Jonathan C.
    [J]. CELL, 2020, 180 (06) : 1044 - 1066
  • [7] Frega G., 2020, Onco Targets Ther, V9
  • [8] The Prognostic Value of Toll-Like Receptors in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis
    Hasnat, Shrabon
    Hujanen, Roosa
    Nwaru, Bright, I
    Salo, Tuula
    Salem, Abdelhakim
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) : 1 - 19
  • [9] Toll-like receptor 5 and 7 expression in adenoid cystic carcinoma of major salivary glands
    Hirvonen, K.
    Back, L.
    Haglund, C.
    Leivo, I.
    Jouhi, L.
    Makitie, A. A.
    Hagstrom, J.
    [J]. TUMOR BIOLOGY, 2016, 37 (08) : 10959 - 10964
  • [10] Jauhiainen Maria K, 2021, Tumour Biol, V43, P249, DOI 10.3233/TUB-211519